In vitro silencing of RIP2 in naive CD4+ T cells from lupus-prone mice promotes pathogenic Th17 cell differentiation
- 5 September 2024
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (11) , 3515-3523
Abstract
Objective This work aims to investigate whether RIP2 silencing in naive CD4+ T cells from lupus-prone mice impacts Th17 cell activity or differentiation in vitro. Methods Naive CD4+ T cells isolation from MRL/lpr mice's spleens. Three RNA interference target sequences of RIP2 were packaged with lentivirus and transfected into naive CD4+ T cells. The shRIP2 with the highest interference efficiency was selected and transfected into naive CD4+ T cells. Naive CD4+ T cells were cultured under conventional (TGF-β1 and IL-6) and pathogenic (IL-6, IL-23, IL-1β) differentiation environments, respectively. Then, RT-qPCR, Western blot or Flow Cytometry were used for measuring the amounts of RIP2 and IL-17 and the differentiation of Th17 cells in two settings. Results Under the conventional Th17 (cTh17) cell differentiation environment (TGF-β1 and IL-6), RIP2 deficiency is linked to decreased IL-17A levels (1.00 ± 0.03 vs 0.80 ± 0.03) and attenuated cTh17 cell (2.46 ± 0.08 vs 0.78 ± 0.03) differentiation (all, P < 0.05). Under the pathogenic Th17 (pTh17) cell environment (IL-1β, IL-23, IL-6), RIP2 deficiency is linked to elevated IL-17A levels (1.03 ± 0.05 vs 1.63 ± 0.07) and enhanced pTh17 cell (3.69 ± 0.19 vs 5.49 ± 0.10) differentiation (all, P < 0.05). Conclusion Our data suggest that RIP2 inhibition induces preferential differentiation of naive CD4+ T cells to pathogenic Th17 cells, while being able to upregulate IL-17A levels in the context of pTh17 cell differentiation. Our study opens up new research areas to reveal the underlying mechanisms and potential therapeutic targets for the prevention and treatment of SLE patients. Key Points • Silencing of RIP2 in naive CD4+ T cells from lupus-prone mice promotes pathogenic Th17 (pTh17) cell differentiation and IL-17A production under pTh17 cell (IL-1β, IL-23, and IL-6) conditions. • RIP2 deficiency in naive CD4+ T cells reduces conventional Th17 (cTh17) cell differentiation and IL-17A production under cTh17 cell (TGF-β1 and IL-6) conditions. • RIP2-deficient naive CD4+ T cells preferentially differentiate towards pTh17 cells rather than cTh17 cells in vitro. • Inhibition of RIP2 may be involved in the development of SLE via effects on Th17/IL-17.Keywords
This publication has 39 references indexed in Scilit:
- Tailored treatment strategies and future directions in systemic lupus erythematosusRheumatology International, 2022
- Immune modulating effects of receptor interacting protein 2 (RIP2) in autoinflammation and immunityClinical Immunology, 2021
- Brief Report: Lupus—An Unrecognized Leading Cause of Death in Young Females: A Population‐Based Study Using Nationwide Death Certificates, 2000–2015Arthritis & Rheumatology, 2018
- RIP2 deficiency attenuates cardiac hypertrophy, inflammation and fibrosis in pressure overload induced miceBiochemical and Biophysical Research Communications, 2017
- Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activityCytokine, 2015
- Increased Th17 Cell Frequency and Poor Clinical Outcome in Rheumatoid Arthritis Are Associated With a Genetic Variant in the IL4R Gene, rs1805010Arthritis & Rheumatology, 2014
- Interleukin-17 Cytokines Are Critical in Development of Fatal Lupus GlomerulonephritisImmunity, 2012
- Signaling via the RIP2 Adaptor Protein in Central Nervous System-Infiltrating Dendritic Cells Promotes Inflammation and AutoimmunityImmunity, 2011
- Th17 and natural Treg cell population dynamics in systemic lupus erythematosusArthritis & Rheumatism, 2009
- Critical Regulation of Early Th17 Cell Differentiation by Interleukin-1 SignalingImmunity, 2009